CHECKMATE 040: EFFICACY, HEPATIC SAFETY, AND BIOMARKERS OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

被引：0
|
作者：
Sangro, Bruno [1 ,2 ]
Hsu, Chiun [3 ]
Kang, Yoon-Koo [4 ]
Kim, Tae-You [5 ]
El-Khoueiry, Anthony [6 ]
Santoro, Armando [7 ]
Melero, Ignacio [8 ]
Kudo, Masatoshi [9 ]
Hou, Ming-Mo [10 ]
Pena, Ana Matilla [11 ]
Tovoli, Francesco [12 ]
Knox, Jennifer J. [13 ]
He, Aiwu Ruth [14 ]
El-Rayes, Bassel [15 ]
Acosta, Mirelis Rivera [16 ]
Lim, Ho-Yeong [17 ]
Neely, Jaclyn [18 ]
Zhao, Huanyu [18 ]
Anderson, Jeffrey [18 ]
Yau, Thomas [19 ]
机构：
[1] Clin Univ Navarra, Idisna, Pamplona, Spain
[2] Ciberehd, Madrid, Spain
[3] Natl Taiwan Univ Hosp, Taipei, Taiwan
[4] Univ Ulsan, Asan Med Ctr, Ulsan, South Korea
[5] Seoul Natl Univ, Seoul, South Korea
[6] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[7] Humanitas Univ, Humanitas Clin & Res Ctr, Rozzano, Italy
[8] Univ Navarra, Pamplona, Spain
[9] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Higashiosaka, Osaka, Japan
[10] Chang Gung Mem Hosp, Taipei, Taiwan
[11] Hosp Gen Univ Gregorio Maranon, Serv Digest, Madrid, Spain
[12] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
[13] Princess Margaret Canc Ctr, Toronto, ON, Canada
[14] Georgetown Univ Hosp, Washington, DC 20007 USA
[15] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[16] Fdn Invest, San Juan, PR USA
[17] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[18] Bristol Myers Squibb, New York, NY USA
[19] Univ Hong Kong, Hong Kong, Peoples R China
来源：
HEPATOLOGY | 2019年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
200
引用
下载
收藏
页码：131A / 132A
页数：2
相关论文
共 50 条
  • [41] Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma
    Su, Y.
    Lin, Y.
    Hsiao, C.
    Ou, D.
    Chen, S.
    Wu, Y.
    Lee, W.
    Lin, J.
    Hsu, C.
    Ho, M.
    Lu, L.
    Wu, T.
    Lai, S.
    Chao, Y.
    Chou, T.
    Yen, C.
    Chen, L.
    Shan, Y.
    Cheng, A.
    Hsu, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S141 - S141
  • [42] Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma
    Takahashi, Akira
    Namikawa, Kenjiro
    Ogata, Dai
    Nakano, Eiji
    Jinnai, Shunichi
    Nakama, Kenta
    Tsutsui, Keita
    Muto, Yusuke
    Mizuta, Haruki
    Yamazaki, Naoya
    JOURNAL OF DERMATOLOGY, 2020, 47 (11): : 1267 - 1275
  • [43] Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma
    Carlino, Matteo S.
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (34) : 3792 - 3793
  • [44] Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and low Karnofsky performance status: Results from the CheckMate 920 trial.
    Hutson, Thomas E.
    Carthon, Bradley Curtis
    Yorio, Jeffrey
    Babu, Sunil
    McKean, Heidi Ann
    Percent, Ivor John
    Tykodi, Scott S.
    Harrison, Michael Roger
    Zhang, Joshua
    Zoco, Jesus
    Johansen, Jennifer L.
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [45] Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study
    Sangro, B.
    Yau, T.
    Hsu, C.
    Kudo, M.
    Crocenzi, T. S.
    Choo, S. -P.
    Meyer, T.
    Welling, T. H., III
    Yeo, W.
    Chopra, A.
    Baakili, A.
    Dela Cruz, C.
    Lang, L.
    Neely, J.
    Melero, I.
    El-Khoueiry, A. B.
    Trojan, J.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S34 - S35
  • [46] Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
    Sznol, Mario
    Ferrucci, Pier Francesco
    Hogg, David
    Atkins, Michael B.
    Wolter, Pascal
    Guidoboni, Massimo
    Lebbe, Celeste
    Kirkwood, John M.
    Schachter, Jacob
    Daniels, Gregory A.
    Hassel, Jessica
    Cebon, Jonathan
    Gerritsen, Winald
    Atkinson, Victoria
    Thomas, Luc
    McCaffrey, John
    Power, Derek
    Walker, Dana
    Bhore, Rafia
    Jiang, Joel
    Hodi, F. Stephen
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (34) : 3815 - +
  • [47] Study to Collect Safety Data and Efficacy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy with Nivolumab or Nivolumab-Ipilimumab Combination
    Rexer, H.
    Gruenwald, V.
    Bedke, J.
    UROLOGE, 2020, 59 (04): : 522 - 523
  • [48] Nivolumab plus Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib
    Tsang, Josephine
    Wong, Jeffrey Sum Lung
    Kwok, Gerry Gin Wai
    Li, Bryan Cho Wing
    Leung, Roland
    Chiu, Joanne
    Cheung, Tan to
    Yau, Thomas
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 15 (06) : 589 - 598
  • [49] PKPD relationship of ipilimumab plus nivolumab combination in patients with advanced melanoma
    Goldwirt, L.
    Louveau, B.
    Liv, T.
    Baroudjian, B.
    Allayous, C.
    Da Meda, L.
    Delyon, J.
    Sauvageon, H.
    Lebbe, C.
    Mourah, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 38 - 38
  • [50] SAFETY PROFILE AND MANAGEMENT OF SELECT TREATMENT-RELATED ADVERSE EVENTS IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) TREATED WITH NIVOLUMAB IN THE CHECKMATE-040 STUDY
    Galway, Aralee
    DiFebo, Holly
    Brutcher, Edith
    Julien, Karen
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
12345